Page last updated: 2024-09-05

darunavir and Cardiovascular Diseases

darunavir has been researched along with Cardiovascular Diseases in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (63.64)24.3611
2020's4 (36.36)2.80

Authors

AuthorsStudies
Siedner, MJ; Triant, VA1
Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M1
Chan, WW; Li, M; Zucker, SD1
Hatleberg, CI; Ryom, L; Sabin, C1
Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A1
Harper, KN1
Guaraldi, G; Raggi, P1
Lundgren, J; Mocroft, A; Ryom, L1
d' Arminio Monforte, A; Dabis, F; De Wit, S; El-Sadr, W; Fontas, E; Hatleberg, CI; Kirk, O; Law, M; Lundgren, JD; Mocroft, A; Phillips, A; Reiss, P; Ryom, L; Sabin, C; Weber, R1
Boven, K; Brown, K; Chavers, S; Dimitrova, D; Luo, D; Mehbob, A; Moecklinghoff, C; Nettles, RE; Opsomer, M; Pai, H; Purrington, A; Vanveggel, S; Verspeelt, J1
Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F1

Reviews

3 review(s) available for darunavir and Cardiovascular Diseases

ArticleYear
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
    Expert opinion on drug safety, 2021, Volume: 20, Issue:11

    Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic

2021
Contemporary protease inhibitors and cardiovascular risk.
    Current opinion in infectious diseases, 2018, Volume: 31, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Risk Assessment; Ritonavir

2018
    Obesity science & practice, 2016, Volume: 2, Issue:1

    Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult

2016

Trials

2 trial(s) available for darunavir and Cardiovascular Diseases

ArticleYear
Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
    Drugs in R&D, 2018, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Risk Factors; Young Adult

2018
    Obesity science & practice, 2016, Volume: 2, Issue:1

    Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult

2016

Other Studies

7 other study(ies) available for darunavir and Cardiovascular Diseases

ArticleYear
Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.
    The Journal of infectious diseases, 2020, 02-03, Volume: 221, Issue:4

    Topics: Atazanavir Sulfate; Cardiovascular Diseases; Case-Control Studies; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Myocardial Infarction; Risk Factors

2020
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
    AIDS (London, England), 2020, 05-01, Volume: 34, Issue:6

    Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome

2020
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
    Journal of the American Heart Association, 2020, 10-20, Volume: 9, Issue:19

    Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors

2020
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
    Atherosclerosis, 2017, Volume: 263

    Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation

2017
Conference on Retroviruses and Opportunistic Infections 2017 highlights.
    AIDS (London, England), 2017, Jun-19, Volume: 31, Issue:10

    Topics: AIDS-Related Opportunistic Infections; Amides; Anti-HIV Agents; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Darunavir; Disease Management; Disease Susceptibility; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Penis; Piperazines; Pyridones; Ritonavir; Treatment Outcome; Washington

2017
Antiretroviral therapies and cardiovascular risk: True or false?
    Atherosclerosis, 2017, Volume: 263

    Topics: Cardiovascular Diseases; Darunavir; HIV; HIV Infections; Humans; Risk Factors

2017
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
    The lancet. HIV, 2018, Volume: 5, Issue:6

    Topics: Adult; Atazanavir Sulfate; Australia; Cardiovascular Diseases; Darunavir; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States

2018